Skip to main content
NIHPA Author Manuscripts logoLink to NIHPA Author Manuscripts
. Author manuscript; available in PMC: 2023 Jul 15.
Published in final edited form as: J Immunol. 2022 Jul 15;209(2):199–207. doi: 10.4049/jimmunol.2200074

Innate and Innate-like Effector Lymphocytes in Health and Disease

Luc Van Kaer *, J Luke Postoak *, Wenqiang Song *, Lan Wu *
PMCID: PMC9285656  NIHMSID: NIHMS1790886  PMID: 35821102

Abstract

Lymphocytes can be functionally partitioned into subsets belonging to the innate or adaptive arms of the immune system. Subsets of innate and innate-like lymphocytes may or may not express antigen-specific receptors of the adaptive immune system, yet are poised to respond with innate-like speed to pathogenic insults but lack the capacity to develop classical immunological memory. These lymphocyte subsets display a number of common properties that permit them to integrate danger and stress signals dispatched by innate sensor cells to facilitate the generation of specialized effector immune responses tailored towards specific pathogens or other insults. Here, we review the functions of distinct subsets of innate and innate-like lymphocytes. A better understanding of the mechanisms by which these cells are activated in different contexts, their interactions with other immune cells, and their role in health and disease may inform the development of new or improved immunotherapies.


The immune response against infection or sterile insults involves coordination between different subsets of lymphocytes and innate effector cells to generate distinct immune effector modules, including a cytotoxic module and three types of helper modules (types 1–3) (1, 2). Innate lymphocytes can respond rapidly to the cytokines produced by innate sensor cells – such as dendritic cells (DCs), macrophages, mast cells and epithelial cells – that are activated by microbe- or damage-associated molecular patterns. Innate lymphocytes activated in this manner may assist myelomonocytic effector cells of the innate immune system as part of the inflammatory response and contribute to the induction of specialized effector T cells and class-switched B cells (3). In turn, adaptive effector lymphocytes amplify the activity of innate lymphocytes and rely on innate effector cells to clear the pathological insult. Hallmarks of an adaptive immune response are the clonal expansion of small numbers of antigen-specific B and T lymphocytes and the generation of long-term memory. Nevertheless, adaptive-like immune responses mediated by some innate lymphocytes such as natural killer (NK) cells have also been described (4), blurring the distinction between innate and adaptive immunity (5). Conversely, several subsets of lymphocytes expressing B or T cell receptors (BCRs or TCRs) exhibit limited capacity to generate classical antigen-specific immune memory responses (6). These innate-like, unconventional B and T cells are enriched in tissues and are further characterized by limited clonal diversity, rapid effector functions, and a tendency for autoreactivity. Additionally, some innate-like, conventional T cells, can generate memory responses in an antigen-independent manner and thus respond rapidly to an immune challenge (7). This Brief Review summarizes the effector and immune functions of the heterogeneous assortment of innate and innate-like lymphocytes (see Figure 1), providing examples of recent progress.

FIGURE 1. Subsets of innate, innate-like and adaptive effector lymphocytes.

FIGURE 1.

Innate lymphocytes are divided into subsets of ILCs and a population of cells expressing iCD3 chains that are unique to the intestinal epithelium. Current nomenclature recognizes five subsets of ILCs: NK cells, three subsets of helper-like ILCs (i.e., ILC1–3), and fetal LTi cells. Innate-like T and B lymphocytes are divided into three groups: 1) innate-like unconventional T cells that include CD1d-restricted NKT cells, MR1-restricted MAIT cells, subsets of γδ T cells, Qa-1/HLA-E-restricted CD8+ T cells, H2-M3-restricted CD8+ T cells, and natural CD8αα+TCRαβ+ IELs, 2) innate-like conventional T cells that include innate and virtual memory CD8+ T cells, and 3) innate-like B cells that include B-1 cells and MZB cells (see Table I for the specificity of these cells). Adaptive lymphocytes are divided into subsets of effector T cells (i.e., CTLs,Th1, Th2, Th17 and Tfh cells, and Tregs) and B cells (i.e., FOB cells). Individual ILC subsets and their respective effector T cell counterparts are color-matched. Created with BioRender.com.

Innate lymphocytes

The family of innate lymphocytes includes 5 subsets of innate lymphoid cells (ILCs) (8) – NK cells, three subsets of helper-like ILCs (ILC1–3), and fetal lymphoid tissue inducer (LTi) cells – and a population of innate intraepithelial lymphocytes (IELs) in the intestine that express T cell markers (Figure 1) (9).

NK cells.

Classical NK cells were originally described as large granular lymphocytes that can lyse tumor cells without prior sensitization (10, 11). NK cells are found widespread throughout lymphoid and nonlymphoid tissues where they may display a remarkable level of phenotypic and functional diversity (12). Their maturation is critically dependent on the transcription factors T-bet and Eomesodermin (Eomes). The reactivity of these cells to susceptible targets is controlled by the balance of signals received from a broad repertoire of activating and inhibitory receptors (13). NK cells can be activated by target cells expressing virus- or stress-induced ligands that engage NK cell activating receptors, or by cells lacking expression of classical MHC class I (class Ia) proteins that engage NK cell inhibitory receptors. NK cells also express Fcγ receptors (FcγRIII/CD16) that, upon interaction with the constant region of IgG antibodies attached to target cells, trigger antibody-dependent cell-mediated cytotoxicity. The activity of these cells is augmented by a variety of cytokines, most notably type I interferons, IL-2, IL-12, IL-15 and IL-18. In addition to exhibiting cytotoxicity via perforin/granzyme and Fas/FasL pathways, activated NK cells are capable of producing cytokines such as IFN-γ and TNF-α, which potently stimulate macrophages and contribute to the generation of cytotoxic and type 1 immunity. As such, NK cells represent the innate counterpart to cytotoxic T lymphocytes in the adaptive immune system.

The role of NK cells in tumor immunosurveillance has been exploited in cancer immunotherapy, for example by adoptive transfer of NK cells engineered to enhance their cytolytic activities (14). NK cells play a critical role in innate defense against viral pathogens, as illustrated by the susceptibility of patients with NK cell deficiency disorders to herpes virus infections (15). These cells also contribute to a multitude of other immune responses, including graft-versus-host disease, allergic inflammation, and autoimmunity. The remarkable heterogeneity of NK cells in different tissues is perhaps best illustrated in the pregnant uterus, where these cells play a critical role in the establishment of the fetal-maternal interface and immune surveillance. For example, a recent study showed that human NK cells in the uterus can clear Listeria monocytogenes bacteria from the developing fetus by delivering the antimicrobial protein granulysin into placental trophoblasts through nanotubes (16). In the central nervous system (CNS), NK cells can modulate cognitive function during aging (17) and neurodegenerative disease (18, 19).

Helper-like ILCs.

Helper-like ILCs are considered the innate counterparts of effector CD4+ T helper (Th) cells, with ILC1, ILC2 and ILC3 exhibiting effector functions similar to Th1, Th2 and Th17 cells, respectively (20, 21). All three helper-like ILC subsets arise from a common progenitor cell characterized by expression of the transcription factor promyelocytic leukemia zinc finger (PLZF) (22), which is also critical for the acquisition of innate effector functions in some subsets of innate-like T cells (see below). They share key transcription factors, homing receptors and cytokine production profiles with their adaptive counterparts. Similar to polarized CD4+ Th cells, helper-like ILCs can respond to their local microenvironment by altering their cytokine profiles and this plasticity may contribute to their biological functions (23). These cells are predominantly tissue resident and particularly abundant at mucosal barrier sites exposed to environmental antigens, commensal microorganisms, and pathogens (24). Although these cells can play critical roles in tissue homeostasis, immune surveillance, and tissue inflammation, patients with a long-term deficiency in helper-like ILCs and NK cells lack a severe clinical phenotype, which has led to the suggestion that these cells may be largely dispensable for warding off disease when normal T and B cell function is preserved (25).

ILC1s are found in a variety of tissues such as liver, small intestine, skin, adipose, uterus, and salivary gland. These cells bear similarities with NK cells such as responsiveness to IL-12 and IL-18 produced by macrophages and DCs, many surface receptors, a requirement of T-bet for their function, and capacity to produce IFN-γ, yet ILC1s require GATA-3 but not Eomes for their differentiation. Although most ILC1s were thought to lack cytotoxicity, new studies have revealed the capacity of many ILC1s to gain cytotoxic potential during effector differentiation, in a manner dependent in part on the transcription factor Hobit (26, 27). IFN-γ produced by these cells can promote macrophage activation and Th1 cell differentiation. Consistent with their similarity to Th1 cells, ILC1s play critical roles in host defense against intracellular bacteria such as L. monocytogenes and Salmonella enterica. They can also promote inflammation and tissue injury such as colitis in the intestine, ischemia-reperfusion injury in the kidney, and adipose tissue inflammation in obesity. Conversely, these cells can protect mice from acute liver injury (28).

ILC2s are most abundant in barrier tissues such as lung, gut and skin. They are activated by the cytokines TSLP (thymic stromal lymphopoietin), IL-25 and IL-33 produced by epithelial cells, require GATA-3 for their development, and upon activation produce the type 2 cytokines IL-5, IL-13, and to a lesser extent IL-4, and also produce the growth factor amphiregulin. In the intestine, activated ILC2s may also produce the immune suppressive cytokine IL-10 (29). ILC2s stimulate mucus production in goblet cells, induce smooth muscle contraction, activate eosinophils, and promote Th2 differentiation to expel helminths such as Nippostrongylus brasiliensis. Surprisingly, the capacity of ILC2s to promote type 2 immunity and helminth expulsion requires their expression of MHC class II and interaction with antigen-specific T cells (30). These cells can also promote airway hyperresponsiveness in viral infections mediated by influenza A virus or respiratory syncytial virus infection. The type 2 cytokines they produce are a major source for the generation of allergic reactions in asthma and atopic dermatitis. ILC2s are also an important source of IL-5 for induction of IgM and IgA antibody production by B-1 cells (31). By producing amphiregulin, these cells can also promote wound healing, a key component of type 2 immunity. In adipose tissue ILC2s promote homeostasis in part by recruiting and maintaining eosinophils and M2 macrophages. Adipose ILC2s can also respond to neurotrophic factors produced by mesenchymal stromal cells, which induces them to produce type 2 cytokines and endogenous opioid peptides that nurture the generation of beige adipocytes, thus promoting energy expenditure and reducing adiposity and obesity (32, 33).

ILC3s are particularly abundant in the gut mucosa and in tonsils, and are also found in spleen, skin and decidua. They are activated by the cytokines IL-1β and IL-23 produced by macrophages and DCs, require the transcription factor RORγt for their development, and can produce the cytokines IL-17 and IL-22. Three subsets of ILC3s can be distinguished based on surface expression of chemokine receptor CCR6 and natural cytotoxicity receptors (NCRs): CCR6NCR+ ILC3s and their CCR6NCR precursors, and CCR6+NCR ILC3s. The latter subset phenotypically resembles fetal LTi cells and is therefore called LTi-like ILC3s. Whereas LTi cells play critical roles in the fetal organogenesis of secondary lymphoid organs (see below), LTi-like ILC3s are important for the postnatal generation of tertiary lymphoid structures such as cryptopatches in the intestine (34).

The effector functions of ILC3s are tightly controlled by the transcription factors RORγt, RORα and T-bet (35, 36). RORγt-deficient mice lack lymph nodes, illustrating the critical role of RORγt-dependent lymphoid cells in lymph node organogenesis. However, the additional absence of T-bet was able to rescue this defect, which was associated with the fetal expansion of RORα-dependent ILC precursors expressing central LTi factors. Since RORγt-deficient mice contain an expanded population of ILC1s, these findings suggest that RORγt opposes the T-bet-driven differentiation of ILC precursors towards the ILC1 lineage.

The cytokines produced by ILC3s can recruit neutrophils, induce antimicrobial peptides, promote epithelial cell survival, facilitate Th17 cell differentiation, and support Tregs in the intestine. Additionally, by providing survival and co-stimulatory signals, ILC3s can enhance T cell-independent IgG3 antibody responses from marginal zone B (MZB) cells (37). ILC3s play critical roles in immune responses against extracellular microbes such as Citrobacter rodentium. Remarkably, the LTi-like ILC3s express MHC class II and can present antigens from commensal microorganisms to CD4+ T cells in the absence of co-stimulation, inhibiting such T cell responses to promote intestinal homeostasis and limit pathological immune responses to commensal microbes (38). Nevertheless, under some conditions such interactions may also promote immune responses in the intestine as well as in the microenvironment of tumors to facilitate tumor immunity (39). Similarly, in a mouse model of multiple sclerosis, MHC class II-expressing ILC3s with an inflammatory phenotype were recruited from the circulation to the CNS and promoted myelin-specific T cell responses and neuroinflammation (40).

Fetal LTi cells.

Fetal LTi cells are closely related to LTi-like ILC3s. Both are dependent on RORγt, but the latter and not the former are derived from a PLZF-expressing precursor (41, 42). Fetal LTi cells are derived from the fetal liver, whereas LTi-like ILC3s are derived from the bone marrow. Fetal LTi cells are critically important for the generation of secondary lymphoid tissues such as the lymph nodes and Peyer patches. Following their generation in the fetal liver, LTi precursors migrate towards the lymph node anlagen where they respond to signals such as retinoic acid and RANK-L (receptor activator of nuclear factor kappa-B ligand) by producing IL-17, IL-22 and especially lymphotoxin, which activates lymphoid tissue organizer cells to promote lymph node development. These cells can also stimulate the generation of tertiary lymphoid structures, but other lymphotoxin-inducing cells can do so as well (43).

Innate IELs expressing CD3 chains.

The intestinal epithelium contains multiple subsets of innate lymphocytes (9). Some of these cells resemble ILC subsets found outside of the intestinal epithelium. Additionally, the intestinal epithelium contains TCR lymphocytes that are developmentally distinct from ILCs, express intracellular CD3 (iCD3) chains, and require IL-15 for their development (44). The latter cells are expanded in a refractory form of celiac disease with the potential to transform into lymphomas. This population of iCD3+ IELs contains a subset (termed iCD8α cells) expressing CD8αα homodimers, which are responsive to cytokines such as IL-12, express MHC class II, exhibit phagocytic properties and produce the cytokines IFN-γ and osteopontin (45). iCD8α cells have been implicated in murine colitis and immune responses against Citrobacter rodentium, and are expanded in human newborn infants with necrotizing enterocolitis (9, 45).

Innate-like B cells

The innate-like B cell population includes B-1 cells and MZB cells (Figure 1 and Table I) (46). These B cell subsets arise from distinct developmental pathways but share many properties and functions.

Table I.

Specificity of innate-like B and T lymphocytes.

Cell type MHC Antigen or other ligand

Innate-like B cells
B-1 N/A self and foreign carbohydrates, glycolipids and glycoproteins
MZB N/A microbial carbohydrates and proteins
Innate-like unconventional T cells
Type I NKT or iNKT CD1d self and microbial glycolipids, including α-linked glycosylceramides such as α-GalCer
Type II NKT or dNKT CD1d self and microbial glycolipids such as sulfatide and lysophosphatidylcholine, and non-lipidic sulfa drugs
MAIT MR1 vitamin B metabolites, small drugs and drug-like molecules
Qa-1/HLA-E-restricted CD8+ T Qa-1 (mouse), HLA-E (human) peptides from MHC class Ia signal sequence, self and microbial heat shock proteins, etc.
H2-M3-restricted CD8+ T H2-M3 (mouse) N-formylated peptides from bacteria or mitochondria
γδ T class Ia, Ib, class I-related, class II, or none peptide, lipid, BTN plus phosphoantigen (human), BTN-like, etc.
Natural TCRαβ+ IELs class Ia or Ib? peptide?
Innate-like conventional T cells
CD8+ innate memory T class Ia peptide
CD8+ virtual memory T class Ia peptide

N/A, not applicable

B-1 cells.

B-1 cells develop early during development from hematopoietic precursors in the fetal yolk sac or fetal liver and maintain their population during adulthood largely by self-renewal (47). B-1 cells constitute a major proportion of the B cells found in the peritoneal and pleural cavities, although they can also be found in other organs such as spleen and adipose tissue. These cells express high surface levels of IgM and low levels of IgD, and also express low levels of CD1d, permitting them to present antigens to natural killer T (NKT) cells (see below). The majority of these cells also express the inhibitory molecule CD5 and are called B-1a cells, whereas those lacking CD5 are called B-1b cells. B-1 cells express a limited BCR repertoire, in part because they undergo recombination in the absence of terminal deoxynucleotidyl transferase (TdT).

B-1a cells are the major source of so-called natural IgM autoantibodies that are reactive to a variety of self-derived carbohydrates, glycolipids and glycoproteins. These autoantibodies are thought to promote the clearance of senescent cells and to react with molecular patterns common to many microbes, thus providing an early source of immunity to diverse pathogens and to protect against sepsis (48). B-1 cells can also produce IgG3 and IgA antibodies in response to host microbiota, to which they react mainly through toll-like receptor (TLR) rather than BCR stimuli, generally in a T cell-independent manner. Although B-1 cell-mediated responses often lack antigen-dependence and immune memory, exceptions have been noted (48).

In addition to antibodies, B-1 cells are potent producers of immunoregulatory cytokines. For example, in response to sepsis or pneumonia, B-1a cells in serosal sites can migrate to the spleen and lung where they differentiate into so-called innate response activator (IRA) B cells that secrete growth factors such as GM-CSF and IL-3, which, in turn, amplify inflammation, while also producing polyreactive IgM antibodies that protect against infection (49). Additionally, a large proportion of B-1 cells can produce immune suppressive cytokines such as IL-10 or IL-27, and are thus included in the burgeoning family of regulatory B cells (Bregs) (5052). These immunoregulatory B-1 cells can protect against sepsis, dissemination of Staphylococcus aureus, autoimmunity, obesity-associated insulin-resistance, and inflammation following myocardial infarction (50, 53, 54).

MZB cells.

MZB cells and follicular B (FOB) cells, jointly called B-2 cells, are derived from a common bone marrow precursor and diverge largely from each other at the transitional T2 stage (55). While new FOB cells are generated throughout life, MZB cells are predominantly generated early in life and are long-lived. MZB cells are located within the marginal zone of the spleen that forms the interface between the lymphoid white pulp and the non-lymphoid red pulp that represents the main point of antigen entry to the organ. Like B-1 cells, MZB cells express high levels of IgM and low levels of IgD. These cells also express CD1d, at levels higher than B-1 cells, but lack expression of CD5. Consistent with their early life origin, most MZB cells generate BCRs without TdT involvement, and exhibit a restricted BCR repertoire similar to B-1 cells that is biased towards common bacterial carbohydrate antigens.

The contribution of MZB cells to the normal pool of natural IgM autoantibodies is likely limited. However, these cells are critical for the rapid generation of T cell-independent IgM and IgG immune responses against blood-borne pathogens. Consequently, individuals without a spleen are at risk of severe disease and sepsis caused by encapsulated bacteria. Such organisms also contain T cell-dependent antigens and MZB cells can generate antibody responses to them as well, following interaction with T follicular helper (Tfh) or NKT cells. A recent study showed that MZB cells can capture peptide-MHC class II complexes from DCs, in a manner that involves binding of complement component C3 with peptide-class II complexes on DCs, followed by plasma membrane transfer to MZB cells via complement receptor 2 in a process called trogocytosis, thus endowing MZB cells with DC-like functions (56). The capacity of MZB cells to generate memory responses remains uncertain.

Like B-1 cells, IL-10-producing MZB cells have been identified. These cells may restrain immune responses against microbial pathogens or autoantigens (50).

Unconventional T cells with innate-like functions

Unconventional T cells are defined as T cells that do not react with classical peptide-MHC complexes (57). This family includes NKT cells, CD1a/b/c-restricted T cells, mucosal-associated invariant T (MAIT) cells, Qa-1/HLA-E-restricted T cells, H2-M3-restricted T cells, γδ T cells, and TCRαβ+CD8αα+ IELs (Figure 1 and Table I) (5761). We will focus here on those subsets that most clearly belong to the group of innate-like T cells, based on their pre-activated state, rapid effector responses, and lack of classical immune memory.

NKT cells.

NKT cells recognize glycolipid antigens presented by the MHC class I-related protein CD1d, which is expressed by a variety of immune and epithelial cells (6267). Two distinct subsets of NKT cells have been recognized: type I or invariant NKT (iNKT) cells that express semi-invariant TCRs (Vα14-Jα18 paired with Vβ8.2, Vβ7, or Vβ2 in mice and Vα24-Jα18 paired with Vβ11 in humans) and type II or diverse NKT (dNKT) cells that express more diverse TCRs (68). In mice, iNKT cells outnumber dNKT cells, whereas in humans, dNKT cells are more prevalent. These cells are enriched in tissues such as liver, but are also found in the intestine, lymphoid organs (including a mature population of iNKT cells in the thymus), and adipose tissue. Both NKT cell subsets can react with a variety of foreign and self-lipid antigens. All iNKT cells react with the prototypical antigen α-galactosylceramide (α-GalCer) that was isolated from a marine sponge but is likely derived from its commensal bacteria (65, 69). This antigen bears striking similarity to the α-linked glycosylceramides produced by some gut microbiota (70) and those serving as endogenous iNKT ligands in mammalian cells (71, 72). Owing to their more diverse TCRs, dNKT cells can react with a broader range of antigens compared to iNKT cells, including the self-lipids sulfatide and β-glucosylceramide, and non-lipidic small molecule sulfa drugs (7375). In addition to TCR stimuli, iNKT cells can be activated by cytokines such as IL-12, IL-18, and type I interferons produced by TLR-activated DCs (76). This latter mode of activation may also apply to dNKT cells, as shown by studies with the TLR9 agonist CpG (77).

Both NKT cell subsets exhibit an effector phenotype, which they acquire during thymic development and requires PLZF expression (7779). For iNKT cells, this also involves the intrathymic generation of subsets – IFN-γ-producing NKT1, IL-4-producing-NKT2 and IL-17-producing NKT17 cells – imprinted with a polarized cytokine production profile (80). Additional PLZF-independent subsets, including IL-10-producing NKT10 cells that are enriched in adipose tissues and IL-21-producing follicular helper NKT (NKTfh) cells, are generated in the periphery. The effector functions of iNKT cells are also significantly shaped by the microbiota they are exposed to early in life (8183). dNKT cells can also produce a variety of cytokines, including IFN-γ, IL-4 and IL-13, but whether these are secreted by distinct subsets remains unclear. The cytokines produced by NKT cells can modulate the activity of a variety of innate, innate-like and adaptive immune cells. Key examples include the capacity of iNKT cells to enhance DC functions, promote NK cell activation, provide help to B cells, and induce Treg cell activity (84).

Owing to their tissue residence, iNKT cells are often one of the first immune cell types to respond to pathogens, including organisms that lack cognate antigens (85). They frequently facilitate protective immune responses against pathogenic microorganisms, but can also contribute to pathology and immune suppression seen following bacterial sepsis (86). iNKT cells also play a role in natural immunity against tumors and contribute to the pathogenesis of a multitude of autoimmune and inflammatory diseases. These activities of iNKT cells have been exploited in vaccines and immune therapies, employing α-GalCer or related antigens (87). dNKT cells can also induce protective (or sometimes pathogenic) immune responses against infectious agents and tumors, and in autoimmune and inflammatory diseases (73, 74, 85). Sulfatide-activated dNKT cells can protect against inflammation of the CNS and liver (73). In some models of cancer or fatty liver disease, iNKT and dNKT cells appear to play opposing roles (74).

MAIT cells.

MAIT cells recognize antigens in the context of the ubiquitously expressed MHC-related 1 (MR1) protein (63, 67, 8890). These cells are rare in mice but quite abundant in humans, and are found in a variety of tissues such as liver, lungs and intestine. Like iNKT cells, MAIT cells express semi-invariant TCRs (Vα19-Jα33 paired with Vβ6 or Vβ8 in mice and Vα7.2-Jα33 paired with Vβ2 or Vβ13 in humans). These cells react with vitamin B metabolites derived from a variety of microorganisms (91). MR1 can also bind with a number of pharmaceutic agents and their derivatives that can weakly stimulate MAIT cells or compete for binding with agonistic antigens (92). Like iNKT cells, these cells can be activated in a TCR-independent manner, by cytokines such as IL-12 and IL-18. Most MAIT cells exhibit an effector phenotype that is acquired in the thymus and requires PLZF expression (93). MAIT cell subsets with a biased cytokine production profile have been identified (88, 94, 95), including IFN-γ-producing MAIT1 cells and a more abundant population of IL-17-producing MAIT17 cells. The MAIT1 and MAIT17 lineages develop in the thymus, which is facilitated by microbiota-derived vitamin B metabolites that traffic to the thymus to expand developing MAIT cells (96). MAIT cells contribute to protective immune responses against a variety of pathogens, including organisms lacking vitamin B biosynthetic pathways. These cells can also positively or negatively influence the progression of autoimmune and inflammatory diseases. Consistent with their response to microbial metabolites, these cells promote intestinal inflammation and dysbiosis, such as during obesity (97). Another critical function of MAIT cells is to promote wound healing by responding to commensal microorganisms (61, 98, 99). The potential utility of MAIT cell antigens as vaccine adjuvants or therapeutics remains to be explored.

Qa-1/HLA-E-restricted T cell subsets.

The murine nonclassical MHC class I (class Ib) protein Qa-1 (encoded by the H2-T23 gene) and its human ortholog HLA-E are ubiquitously expressed and can bind with peptides derived from a variety of endogenous and exogenous sources (100, 101). Qa-1 is typically occupied by peptides derived from the signal sequence of MHC class Ia proteins, and this complex interacts with CD94/NKG2 receptors on NK cells and subsets of CD8 T cells, leading to inhibition (via CD94/NKG2A) or less commonly activation (via CD94/NKG2C). Qa-1 can also bind with peptides derived from host or bacterial heat shock proteins, insulin, TCR Vβ chains, and a variety of self-peptides that are enriched in cells deficient in factors (i.e., TAP [transporter associated with antigen processing] or ERAAP [ER-associated aminopeptidase]) controlling MHC class I-restricted antigen presentation (102, 103). The Qa-1-restricted CD8 T cells reactive to some of these antigens may exhibit pro- or anti-inflammatory responses in different contexts (101, 104, 105). A regulatory Qa-1-restricted T cell population that expresses CD8αα and PLZF has been identified in the liver, and these cells can restrain autoimmunity in the CNS and intestine (106). The Qa-1-restricted CD8 T cell populations specific for immunodominant ligands on TAP- or ERAAP-deficient cells showed features of innate-like T cells, including expression of an invariant TCRα chain and a memory phenotype (102, 103). Upon activation, these cells became cytotoxic and produced IFN-γ, but their immune functions remain unclear. Finally, a population of HLA-E-restricted CD8+ T cells expands during human cytomegalovirus infection to adopt an NK cell-like phenotype with the capacity to lyse virally-infected cells via engagement of CD94/NKG2C in the absence of TCR stimulation (107).

H2-M3-restricted T cells.

The ubiquitously expressed mouse class Ib protein H2-M3 binds with N-formylated peptides (108), and is thus uniquely suited to present bacterially or mitochondrially derived peptides to CD8 T cells. Although H2-M3-restricted CD8 T cells display a diverse TCR repertoire, they exhibit a pre-activated phenotype to rapidly gain cytotoxicity and produce IFN-γ to bacterial pathogens, and generate diminished memory responses (105, 109111). They play a non-redundant role in protective immunity against L. monocytogenes infection (112, 113). A recent study showed that these cells produce IL-17 and amphiregulin to commensal bacteria in the skin, providing antimicrobial protection while accelerating skin wound healing (114).

γδ T cell subsets.

γδ T cells are most abundant in barrier tissues, including skin, intestine and lungs, where subsets expressing particular TCR Vγ and Vδ combinations reside (115, 116). Subsets of γδ T cells with a variety of specificities have been identified. For example, human Vγ9Vδ2 T cells react with bacterial phosphoantigens bound by members of the butyrophilin (BTN) family of proteins that are related to the B7 family of co-stimulatory molecules. BTN-like proteins also control the development and function of γδ T cells in the skin of mice (i.e., DETC [dendritic epidermal T cells]) and in the intestinal epithelium of mice and humans (i.e., natural γδ IELs). Other subsets of γδ T cells interact with MHC class I-related proteins such as CD1, MR1, mouse T10/T22, human MICA and MICB (MHC class I-related A and B), and UL16-binding protein 4 (ULBP4), either in the presence (e.g., CD1, MR1) or absence (e.g., T10/T22, MICA/B, and ULBP4) of bound antigen (117). Some of these factors may be induced by cellular stress and also activate γδ T cells by binding with NKG2D (e.g., MICA/B and ULBPs). γδ T cell subsets develop in waves from embryonic to early neonatal life to populate specific peripheral sites. Subsets of γδ T cells (γδT1, γδT2 and γδT17 cells) that are thymically programmed to produce type 1–3 cytokines have been described, and some (γδT2 and γδT17 subsets) are dependent on PLZF for their development (80, 118). In addition to TCR- and NKG2D-mediated responses, these cells can be activated by cytokines such as IL-12 and IL-18. Although some γδ T cells can generate immune memory, others cannot (119). Consistent with their diverse tissue distribution and effector functions, γδ T cells have been implicated in protective immune responses against a variety of pathogens, can contribute either positively or negatively to tumor immunity, and control the pathogenesis of autoimmune and inflammatory diseases (115, 116). For example, recent studies with human Vγ9Vδ2 T cells have shown two pathways by which these cells can sense and constrain blood stage malaria parasite infection (120): firstly, their TCRs can interact with parasite-derived phosphoantigens bound with BTN proteins on red blood cells to trigger red blood cell lysis, and secondly, in the presence of patient serum, these cells can phagocytose and degrade the malaria parasites. Other recent studies have identified a subset of γδT17 cells that accumulate in adipose tissue where they are able to influence Treg cell homeostasis, promote sympathetic innervation, and control thermogenesis (121, 122). DETC that reside in the murine epidermis have been implicated in regulating cutaneous malignancy and skin antimicrobial barrier function (123, 124). Finally, natural γδ IELs in the intestine play a role in parasite expulsion, tissue repair following mucosal injury, and oral tolerance (9, 125).

Natural TCRαβ+CD8αα+ IELs.

In addition to innate IELs and natural γδ IELs discussed above, the intestinal epithelium contains αβ IELs with innate-like characteristics and functions (9, 125). These natural αβ IELs express CD8αα in the absence of CD8αβ or CD4 and are derived from thymic precursors that upon leaving the thymus during a narrow time window in early life rapidly seed the epithelium and induce CD8αα expression in response to TGF-β signaling (9, 125, 126). The specificity of these cells is uncertain but likely involves both classical and nonclassical MHC products. These cells display an oligoclonal TCR repertoire, exhibit an effector or memory phenotype, depend on IL-15 for their maintenance and/or differentiation, and show similarities with thymus-derived Tregs (127). The functions of these cells are incompletely understood, but they may be involved in sensing damaged epithelia and regulating intestinal inflammation (9, 125). Recent studies have shown that natural TCR+ IELs can modulate systemic metabolism and accelerate cardiovascular disease to a fat- and sugar-rich diet (128).

Conventional T cells with innate-like functions

A substantial proportion of antigen-inexperienced T cells in unmanipulated mice express phenotypic markers of immune memory (7, 129, 130). These cells have been primarily defined within the CD8+ T cell lineage of mice. These antigen-inexperienced memory T cells can be partitioned into subsets whose innate-like memory phenotype is imprinted intra-thymically (i.e., innate memory T cells) or acquired extra-thymically (i.e., virtual memory T cells) (Figure 1 and Table I). Although the precise developmental, phenotypic and functional relationships between these two subsets are under debate (7), it has been recently suggested that these subsets can be distinguished based on differential surface expression levels of CD122 (131). Thymic innate memory CD8+ T cells are formed via IL-4 produced by NKT2 cells and prevail in young mice with high thymic IL-4 output (131, 132). Virtual memory T cells are thought to represent CD8 T cells with high levels of autoreactivity that are converted to innate-like memory T cells in the periphery via cytokines such as IL-15, IL-7 and/or IL-4 (133135). Virtual memory T cells are more prevalent in aged mice, probably owing to age-related lymphopenia (136). Innate-like memory T cells express NKG2D and can respond to cytokine signals (e.g., IL-12 and IL-18) to induce IFN-γ production and bystander killing in an antigen-independent manner. These cells contribute to clearance of bacterial and viral infections while maintaining tolerance against self-antigens (7, 129, 130). These cells can also infiltrate tumors where they express PD-1 (programmed death 1) and may serve as targets for checkpoint inhibitors (133).

Conclusions

Innate and innate-like lymphocytes can sense danger and stress signals that evoke their rapid effector responses to promote early immune surveillance and modulate adaptive immunity. Distinct subsets of innate and innate-like lymphocytes exhibit specialized effector functions that mirror those of their adaptive cousins. These cells therefore play integral roles in each of the major immune effector modules. Despite this progress, many questions regarding the diverse functions of innate and innate-like lymphocytes remain to be fully addressed (Table II). A better understanding of the biology of these cells and their roles in health and disease will undoubtedly advance novel approaches for the development of vaccines and immunotherapies.

Table II.

Outstanding questions regarding the functions of innate and innate-like effector lymphocytes.

How similar or different are they between humans and mice?
What are the mechanisms that elicit their effector functions?
To what extent do tissues imprint resident populations with unique features?
How do they interact with other immune and non-immune cells?
Are the functions of individual subsets redundant or unique?
Do they make distinct contributions to primary vs. secondary immune responses?
Considering the alterations observed in some of these cells during SARS-CoV-2 infection (137140), do they influence COVID-19 disease progression?
How can we better target these cells in vaccines and immunotherapies?

Acknowledgements

We apologize to the many colleagues whose work we did not cite due to space constraints or omission.

This work was supported by grants from the NIH (R01AI139046) and the American Heart Association (19TPA34910078).

Abbreviations used in this article:

Breg

regulatory B

BTN

butyrophilin

DETC

dendritic epidermal T cell

dNKT

diverse NKT

Eomes

Eomesodermin

FOB

follicular B

IEL

intraepithelial lymphocyte

ILC

innate lymphoid cell

iNKT

invariant NKT

LTi

lymphoid tissue inducer

MAIT

mucosal-associated invariant T

MIC

MHC class I-related

MR1

MHC-related 1

MZB

marginal zone B

NCR

natural cytotoxicity receptor

NK

natural killer

NKT

natural killer T

PLZF

promyelocytic leukemia zinc finger

Tfh

T follicular helper

Treg

regulatory T

ULBP

UL16-binding protein

Footnotes

Disclosures

LVK is a member of the scientific advisory board of Isu Abxis Co., Ltd. (South Korea). None of the other authors have financial conflicts of interest.

References

  • 1.Murphy K, Weaver C, and Berg L. 2022. Janeway’s Immunobiology. 10th ed., W. W. Norton and Company, Inc., New York. [Google Scholar]
  • 2.Annunziato F, Romagnani C, and Romagnani S. 2015. The 3 major types of innate and adaptive cell-mediated effector immunity. J Allergy Clin Immunol 135: 626–635. [DOI] [PubMed] [Google Scholar]
  • 3.Gasteiger G, and Rudensky AY 2014. Interactions between innate and adaptive lymphocytes. Nat Rev Immunol 14: 631–639. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Mujal AM, Delconte RB, and Sun JC 2021. Natural Killer Cells: From Innate to Adaptive Features. Annu Rev Immunol 39: 417–447. [DOI] [PubMed] [Google Scholar]
  • 5.Lanier LL 2013. Shades of grey--the blurring view of innate and adaptive immunity. Nat Rev Immunol 13: 73–74. [DOI] [PubMed] [Google Scholar]
  • 6.Bendelac A, Bonneville M, and Kearney JF 2001. Autoreactivity by design: innate B and T lymphocytes. Nat Rev Immunol 1: 177–186. [DOI] [PubMed] [Google Scholar]
  • 7.White JT, Cross EW, and Kedl RM 2017. Antigen-inexperienced memory CD8. Nat Rev Immunol 17: 391–400. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Vivier E, Artis D, Colonna M, Diefenbach A, Di Santo JP, Eberl G, Koyasu S, Locksley RM, McKenzie ANJ, Mebius RE, Powrie F, and Spits H. 2018. Innate Lymphoid Cells: 10 Years On. Cell 174: 1054–1066. [DOI] [PubMed] [Google Scholar]
  • 9.Olivares-Villagómez D, and Van Kaer L. 2018. Intestinal Intraepithelial Lymphocytes: Sentinels of the Mucosal Barrier. Trends Immunol 39: 264–275. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Sun JC, and Lanier LL 2011. NK cell development, homeostasis and function: parallels with CD8⁺ T cells. Nat Rev Immunol 11: 645–657. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Yokoyama W. 2013. Chapter 17: Natural killer cells. 6th ed., Paul WE, ed., Wolters Kluwer, Philadelphia. [Google Scholar]
  • 12.Shi FD, Ljunggren HG, La Cava A, and Van Kaer L. 2011. Organ-specific features of natural killer cells. Nat Rev Immunol 11: 658–671. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Lanier LL 2008. Up on the tightrope: natural killer cell activation and inhibition. Nat Immunol 9: 495–502. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Chiossone L, Dumas PY, Vienne M, and Vivier E. 2018. Natural killer cells and other innate lymphoid cells in cancer. Nat Rev Immunol 18: 671–688. [DOI] [PubMed] [Google Scholar]
  • 15.Mace EM, and Orange JS 2019. Emerging insights into human health and NK cell biology from the study of NK cell deficiencies. Immunol Rev 287: 202–225. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Crespo Â, Mulik S, Dotiwala F, Ansara JA, Sen Santara S, Ingersoll K, Ovies C, Junqueira C, Tilburgs T, Strominger JL, and Lieberman J. 2020. Decidual NK Cells Transfer Granulysin to Selectively Kill Bacteria in Trophoblasts. Cell 182: 1125–1139.e1118. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Jin WN, Shi K, He W, Sun JH, Van Kaer L, Shi FD, and Liu Q. 2021. Neuroblast senescence in the aged brain augments natural killer cell cytotoxicity leading to impaired neurogenesis and cognition. Nat Neurosci 24: 61–73. [DOI] [PubMed] [Google Scholar]
  • 18.Earls RH, Menees KB, Chung J, Gutekunst CA, Lee HJ, Hazim MG, Rada B, Wood LB, and Lee JK 2020. NK cells clear α-synuclein and the depletion of NK cells exacerbates synuclein pathology in a mouse model of α-synucleinopathy. Proc Natl Acad Sci U S A 117: 1762–1771. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Zhang Y, Fung ITH, Sankar P, Chen X, Robison LS, Ye L, D’Souza SS, Salinero AE, Kuentzel ML, Chittur SV, Zhang W, Zuloaga KL, and Yang Q. 2020. Depletion of NK Cells Improves Cognitive Function in the Alzheimer Disease Mouse Model. J Immunol 205: 502–510. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Guia S, and Narni-Mancinelli E. 2020. Helper-like Innate Lymphoid Cells in Humans and Mice. Trends Immunol 41: 436–452. [DOI] [PubMed] [Google Scholar]
  • 21.Colonna M. 2018. Innate Lymphoid Cells: Diversity, Plasticity, and Unique Functions in Immunity. Immunity 48: 1104–1117. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Constantinides MG, McDonald BD, Verhoef PA, and Bendelac A. 2014. A committed precursor to innate lymphoid cells. Nature 508: 397–401. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Bal SM, Golebski K, and Spits H. 2020. Plasticity of innate lymphoid cell subsets. Nat Rev Immunol 20: 552–565. [DOI] [PubMed] [Google Scholar]
  • 24.Meininger I, Carrasco A, Rao A, Soini T, Kokkinou E, and Mjösberg J. 2020. Tissue-Specific Features of Innate Lymphoid Cells. Trends Immunol 41: 902–917. [DOI] [PubMed] [Google Scholar]
  • 25.Vély F, Barlogis V, Vallentin B, Neven B, Piperoglou C, Ebbo M, Perchet T, Petit M, Yessaad N, Touzot F, Bruneau J, Mahlaoui N, Zucchini N, Farnarier C, Michel G, Moshous D, Blanche S, Dujardin A, Spits H, Distler JH, Ramming A, Picard C, Golub R, Fischer A, and Vivier E. 2016. Evidence of innate lymphoid cell redundancy in humans. Nat Immunol 17: 1291–1299. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Friedrich C, Taggenbrock RLRE, Doucet-Ladevèze R, Golda G, Moenius R, Arampatzi P, Kragten NAM, Kreymborg K, Gomez de Agüero M, Kastenmüller W, Saliba AE, Grün D, van Gisbergen KPJM, and Gasteiger G. 2021. Effector differentiation downstream of lineage commitment in ILC1s is driven by Hobit across tissues. Nat Immunol 22: 1256–1267. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Yomogida K, Bigley TM, Trsan T, Gilfillan S, Cella M, Yokoyama WM, Egawa T, and Colonna M. 2021. Hobit confers tissue-dependent programs to type 1 innate lymphoid cells. Proc Natl Acad Sci U S A 118: e2117965118. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Nabekura T, Riggan L, Hildreth AD, O’Sullivan TE, and Shibuya A. 2020. Type 1 Innate Lymphoid Cells Protect Mice from Acute Liver Injury via Interferon-γ Secretion for Upregulating Bcl-xL Expression in Hepatocytes. Immunity 52: 96–108.e109. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Bando JK, Gilfillan S, Di Luccia B, Fachi JL, Sécca C, Cella M, and Colonna M. 2020. ILC2s are the predominant source of intestinal ILC-derived IL-10. J Exp Med 217: e20191520. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.Oliphant CJ, Hwang YY, Walker JA, Salimi M, Wong SH, Brewer JM, Englezakis A, Barlow JL, Hams E, Scanlon ST, Ogg GS, Fallon PG, and McKenzie AN 2014. MHCII-mediated dialog between group 2 innate lymphoid cells and CD4(+) T cells potentiates type 2 immunity and promotes parasitic helminth expulsion. Immunity 41: 283–295. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31.Jackson-Jones LH, Duncan SM, Magalhaes MS, Campbell SM, Maizels RM, McSorley HJ, Allen JE, and Bénézech C. 2016. Fat-associated lymphoid clusters control local IgM secretion during pleural infection and lung inflammation. Nat Commun 7: 12651. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.Brestoff JR, Kim BS, Saenz SA, Stine RR, Monticelli LA, Sonnenberg GF, Thome JJ, Farber DL, Lutfy K, Seale P, and Artis D. 2015. Group 2 innate lymphoid cells promote beiging of white adipose tissue and limit obesity. Nature 519: 242–246. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33.Cardoso F, Klein Wolterink RGJ, Godinho-Silva C, Domingues RG, Ribeiro H, da Silva JA, Mahú I, Domingos AI, and Veiga-Fernandes H. 2021. Neuro-mesenchymal units control ILC2 and obesity via a brain-adipose circuit. Nature 597: 410–414. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34.Shikhagaie MM, Björklund Å, Mjösberg J, Erjefält JS, Cornelissen AS, Ros XR, Bal SM, Koning JJ, Mebius RE, Mori M, Bruchard M, Blom B, and Spits H. 2017. Neuropilin-1 Is Expressed on Lymphoid Tissue Residing LTi-like Group 3 Innate Lymphoid Cells and Associated with Ectopic Lymphoid Aggregates. Cell Rep 18: 1761–1773. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35.Stehle C, Rückert T, Fiancette R, Gajdasik DW, Willis C, Ulbricht C, Durek P, Mashreghi MF, Finke D, Hauser AE, Withers DR, Chang HD, Zimmermann J, and Romagnani C. 2021. T-bet and RORα control lymph node formation by regulating embryonic innate lymphoid cell differentiation. Nat Immunol 22: 1231–1244. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 36.Fiancette R, Finlay CM, Willis C, Bevington SL, Soley J, Ng STH, Baker SM, Andrews S, Hepworth MR, and Withers DR 2021. Reciprocal transcription factor networks govern tissue-resident ILC3 subset function and identity. Nat Immunol 22: 1245–1255. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 37.Magri G, Miyajima M, Bascones S, Mortha A, Puga I, Cassis L, Barra CM, Comerma L, Chudnovskiy A, Gentile M, Llige D, Cols M, Serrano S, Aróstegui JI, Juan M, Yagüe J, Merad M, Fagarasan S, and Cerutti A. 2014. Innate lymphoid cells integrate stromal and immunological signals to enhance antibody production by splenic marginal zone B cells. Nat Immunol 15: 354–364. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38.Hepworth MR, Fung TC, Masur SH, Kelsen JR, McConnell FM, Dubrot J, Withers DR, Hugues S, Farrar MA, Reith W, Eberl G, Baldassano RN, Laufer TM, Elson CO, and Sonnenberg GF 2015. Immune tolerance. Group 3 innate lymphoid cells mediate intestinal selection of commensal bacteria-specific CD4⁺ T cells. Science 348: 1031–1035. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 39.Goc J, Lv M, Bessman NJ, Flamar AL, Sahota S, Suzuki H, Teng F, Putzel GG, Eberl G, Withers DR, Arthur JC, Shah MA, Sonnenberg GF, and Bank JLC 2021. Dysregulation of ILC3s unleashes progression and immunotherapy resistance in colon cancer. Cell 184: 5015–5030.e5016. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 40.Grigg JB, Shanmugavadivu A, Regen T, Parkhurst CN, Ahmed A, Joseph AM, Mazzucco M, Gronke K, Diefenbach A, Eberl G, Vartanian T, Waisman A, and Sonnenberg GF 2021. Antigen-presenting innate lymphoid cells orchestrate neuroinflammation. Nature 600: 707–712. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 41.van de Pavert SA 2021. Lymphoid Tissue inducer (LTi) cell ontogeny and functioning in embryo and adult. Biomed J 44: 123–132. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 42.Ishizuka IE, Chea S, Gudjonson H, Constantinides MG, Dinner AR, Bendelac A, and Golub R. 2016. Single-cell analysis defines the divergence between the innate lymphoid cell lineage and lymphoid tissue-inducer cell lineage. Nat Immunol 17: 269–276. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 43.Jacquelot N, Tellier J, Nutt SL, and Belz GT 2021. Tertiary lymphoid structures and B lymphocytes in cancer prognosis and response to immunotherapies. Oncoimmunology 10: e1900508. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 44.Ettersperger J, Montcuquet N, Malamut G, Guegan N, Lopez-Lastra S, Gayraud S, Reimann C, Vidal E, Cagnard N, Villarese P, Andre-Schmutz I, Gomes Domingues R, Godinho-Silva C, Veiga-Fernandes H, Lhermitte L, Asnafi V, Macintyre E, Cellier C, Beldjord K, Di Santo JP, Cerf-Bensussan N, and Meresse B. 2016. Interleukin-15-Dependent T-Cell-like Innate Intraepithelial Lymphocytes Develop in the Intestine and Transform into Lymphomas in Celiac Disease. Immunity 45: 610–625. [DOI] [PubMed] [Google Scholar]
  • 45.Van Kaer L, Algood HMS, Singh K, Parekh VV, Greer MJ, Piazuelo MB, Weitkamp JH, Matta P, Chaturvedi R, Wilson KT, and Olivares-Villagómez D. 2014. CD8αα⁺ innate-type lymphocytes in the intestinal epithelium mediate mucosal immunity. Immunity 41: 451–464. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 46.Grasseau A, Boudigou M, Le Pottier L, Chriti N, Cornec D, Pers JO, Renaudineau Y, and Hillion S. 2020. Innate B Cells: the Archetype of Protective Immune Cells. Clin Rev Allergy Immunol 58: 92–106. [DOI] [PubMed] [Google Scholar]
  • 47.Baumgarth N. 2011. The double life of a B-1 cell: self-reactivity selects for protective effector functions. Nat Rev Immunol 11: 34–46. [DOI] [PubMed] [Google Scholar]
  • 48.Smith FL, and Baumgarth N. 2019. B-1 cell responses to infections. Curr Opin Immunol 57: 23–31. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 49.Chousterman BG, and Swirski FK 2015. Innate response activator B cells: origins and functions. Int Immunol 27: 537–541. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 50.Rosser EC, and Mauri C. 2015. Regulatory B cells: origin, phenotype, and function. Immunity 42: 607–612. [DOI] [PubMed] [Google Scholar]
  • 51.Lino AC, Dang VD, Lampropoulou V, Welle A, Joedicke J, Pohar J, Simon Q, Thalmensi J, Baures A, Flühler V, Sakwa I, Stervbo U, Ries S, Jouneau L, Boudinot P, Tsubata T, Adachi T, Hutloff A, Dörner T, Zimber-Strobl U, de Vos AF, Dahlke K, Loh G, Korniotis S, Goosmann C, Weill JC, Reynaud CA, Kaufmann SHE, Walter J, and Fillatreau S. 2018. LAG-3 Inhibitory Receptor Expression Identifies Immunosuppressive Natural Regulatory Plasma Cells. Immunity 49: 120–133.e129. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 52.Choi JK, Yu CR, Bing SJ, Jittayasothorn Y, Mattapallil MJ, Kang M, Park SB, Lee HS, Dong L, Shi G, Caspi RR, and Egwuagu CE 2021. IL-27-producing B-1a cells suppress neuroinflammation and CNS autoimmune diseases. Proc Natl Acad Sci U S A 118: e2109548118. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 53.Wu L, Parekh VV, Hsiao J, Kitamura D, and Van Kaer L. 2014. Spleen supports a pool of innate-like B cells in white adipose tissue that protects against obesity-associated insulin resistance. Proc Natl Acad Sci U S A 111: E4638–4647. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 54.Wu L, Dalal R, Cao CD, Postoak JL, Yang G, Zhang Q, Wang Z, Lal H, and Van Kaer L. 2019. IL-10-producing B cells are enriched in murine pericardial adipose tissues and ameliorate the outcome of acute myocardial infarction. Proc Natl Acad Sci U S A 116: 21673–21684. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 55.Cerutti A, Cols M, and Puga I. 2013. Marginal zone B cells: virtues of innate-like antibody-producing lymphocytes. Nat Rev Immunol 13: 118–132. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 56.Schriek P, Ching AC, Moily NS, Moffat J, Beattie L, Steiner TM, Hosking LM, Thurman JM, Holers VM, Ishido S, Lahoud MH, Caminschi I, Heath WR, Mintern JD, and Villadangos JA 2022. Marginal zone B cells acquire dendritic cell functions by trogocytosis. Science 375: eabf7470. [DOI] [PubMed] [Google Scholar]
  • 57.Godfrey DI, Uldrich AP, McCluskey J, Rossjohn J, and Moody DB 2015. The burgeoning family of unconventional T cells. Nat Immunol 16: 1114–1123. [DOI] [PubMed] [Google Scholar]
  • 58.Legoux F, Salou M, and Lantz O. 2017. Unconventional or Preset αβ T Cells: Evolutionarily Conserved Tissue-Resident T Cells Recognizing Nonpeptidic Ligands. Annu Rev Cell Dev Biol 33: 511–535. [DOI] [PubMed] [Google Scholar]
  • 59.Mayassi T, Barreiro LB, Rossjohn J, and Jabri B. 2021. A multilayered immune system through the lens of unconventional T cells. Nature 595: 501–510. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 60.Van Kaer L. 2021. Preface: Unconventional T cells in health and disease. Crit Rev Immunol 41: v–ix. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 61.Constantinides MG, and Belkaid Y. 2021. Early-life imprinting of unconventional T cells and tissue homeostasis. Science 374: eabf0095. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 62.Brigl M, and Brenner MB 2004. CD1: antigen presentation and T cell function. Annu Rev Immunol 22: 817–890. [DOI] [PubMed] [Google Scholar]
  • 63.Salio M, Silk JD, Jones EY, and Cerundolo V. 2014. Biology of CD1- and MR1-restricted T cells. Annu Rev Immunol 32: 323–366. [DOI] [PubMed] [Google Scholar]
  • 64.Kronenberg M. 2005. Toward an understanding of NKT cell biology: progress and paradoxes. Annu Rev Immunol 23: 877–900. [DOI] [PubMed] [Google Scholar]
  • 65.Bendelac A, Savage PB, and Teyton L. 2007. The biology of NKT cells. Annu Rev Immunol 25: 297–336. [DOI] [PubMed] [Google Scholar]
  • 66.Taniguchi M, Harada M, Kojo S, Nakayama T, and Wakao H. 2003. The regulatory role of Valpha14 NKT cells in innate and acquired immune response. Annu Rev Immunol 21: 483–513. [DOI] [PubMed] [Google Scholar]
  • 67.Iwabuchi K, and Van Kaer L. 2019. Editorial: Role of CD1- and MR1-Restricted T Cells in Immunity and Disease. Front Immunol 10: Article 1837. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 68.Godfrey DI, MacDonald HR, Kronenberg M, Smyth MJ, and Van Kaer L. 2004. NKT cells: what’s in a name? Nat Rev Immunol 4: 231–237. [DOI] [PubMed] [Google Scholar]
  • 69.Kawano T, Cui J, Koezuka Y, Toura I, Kaneko Y, Motoki K, Ueno H, Nakagawa R, Sato H, Kondo E, Koseki H, and Taniguchi M. 1997. CD1d-restricted and TCR-mediated activation of valpha14 NKT cells by glycosylceramides. Science 278: 1626–1629. [DOI] [PubMed] [Google Scholar]
  • 70.Oh SF, Praveena T, Song H, Yoo JS, Jung DJ, Erturk-Hasdemir D, Hwang YS, Lee CC, Le Nours J, Kim H, Lee J, Blumberg RS, Rossjohn J, Park SB, and Kasper DL 2021. Host immunomodulatory lipids created by symbionts from dietary amino acids. Nature 600: 302–307. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 71.Kain L, Webb B, Anderson BL, Deng S, Holt M, Costanzo A, Constanzo A, Zhao M, Self K, Teyton A, Everett C, Kronenberg M, Zajonc DM, Bendelac A, Savage PB, and Teyton L. 2014. The identification of the endogenous ligands of natural killer T cells reveals the presence of mammalian α-linked glycosylceramides. Immunity 41: 543–554. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 72.Brennan PJ, Tatituri RV, Heiss C, Watts GF, Hsu FF, Veerapen N, Cox LR, Azadi P, Besra GS, and Brenner MB 2014. Activation of iNKT cells by a distinct constituent of the endogenous glucosylceramide fraction. Proc Natl Acad Sci U S A 111: 13433–13438. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 73.Singh AK, Tripathi P, and Cardell SL 2018. Type II NKT Cells: An Elusive Population With Immunoregulatory Properties. Front Immunol 9: Article 1969. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 74.Dhodapkar MV, and Kumar V. 2017. Type II NKT Cells and Their Emerging Role in Health and Disease. J Immunol 198: 1015–1021. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 75.Almeida CF, Smith DGM, Cheng TY, Harpur CM, Batleska E, Nguyen-Robertson CV, Nguyen T, Thelemann T, Reddiex SJJ, Li S, Eckle SBG, Van Rhijn I, Rossjohn J, Uldrich AP, Moody DB, Williams SJ, Pellicci DG, and Godfrey DI 2021. Benzofuran sulfonates and small self-lipid antigens activate type II NKT cells via CD1d. Proc Natl Acad Sci U S A 118: e2104420118. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 76.Joyce S, Okoye GD, and Van Kaer L. 2021. Natural killer T lymphocytes integrate innate sensory information and relay context to effector immune responses. Crit Rev Immunol 41: 55–88. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 77.Zhao J, Weng X, Bagchi S, and Wang CR 2014. Polyclonal type II natural killer T cells require PLZF and SAP for their development and contribute to CpG-mediated antitumor response. Proc Natl Acad Sci U S A 111: 2674–2679. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 78.Kovalovsky D, Uche OU, Eladad S, Hobbs RM, Yi W, Alonzo E, Chua K, Eidson M, Kim HJ, Im JS, Pandolfi PP, and Sant’Angelo DB 2008. The BTB-zinc finger transcriptional regulator PLZF controls the development of invariant natural killer T cell effector functions. Nat Immunol 9: 1055–1064. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 79.Savage AK, Constantinides MG, Han J, Picard D, Martin E, Li B, Lantz O, and Bendelac A. 2008. The transcription factor PLZF directs the effector program of the NKT cell lineage. Immunity 29: 391–403. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 80.Pellicci DG, Koay HF, and Berzins SP 2020. Thymic development of unconventional T cells: how NKT cells, MAIT cells and γδ T cells emerge. Nat Rev Immunol 20: 756–770. [DOI] [PubMed] [Google Scholar]
  • 81.Wei B, Wingender G, Fujiwara D, Chen DY, McPherson M, Brewer S, Borneman J, Kronenberg M, and Braun J. 2010. Commensal microbiota and CD8+ T cells shape the formation of invariant NKT cells. J Immunol 184: 1218–1226. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 82.Wingender G, Stepniak D, Krebs P, Lin L, McBride S, Wei B, Braun J, Mazmanian SK, and Kronenberg M. 2012. Intestinal microbes affect phenotypes and functions of invariant natural killer T cells in mice. Gastroenterology 143: 418–428. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 83.Olszak T, An D, Zeissig S, Vera MP, Richter J, Franke A, Glickman JN, Siebert R, Baron RM, Kasper DL, and Blumberg RS 2012. Microbial exposure during early life has persistent effects on natural killer T cell function. Science 336: 489–493. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 84.Van Kaer L, Parekh VV, and Wu L. 2013. Invariant natural killer T cells as sensors and managers of inflammation. Trends Immunol 34: 50–58. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 85.Vogt S, and Mattner J. 2021. NKT Cells Contribute to the Control of Microbial Infections. Front Cell Infect Microbiol 11: Article 718350. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 86.Kim EY, Ner-Gaon H, Varon J, Cullen AM, Guo J, Choi J, Barragan-Bradford D, Higuera A, Pinilla-Vera M, Short SA, Arciniegas-Rubio A, Tamura T, Leaf DE, Baron RM, Shay T, and Brenner MB 2020. Post-sepsis immunosuppression depends on NKT cell regulation of mTOR/IFN-γ in NK cells. J Clin Invest 130: 3238–3252. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 87.Van Kaer L, Parekh VV, and Wu L. 2011. Invariant NK T cells: potential for immunotherapeutic targeting with glycolipid antigens. Immunotherapy 3: 59–75. [DOI] [PubMed] [Google Scholar]
  • 88.Godfrey DI, Koay HF, McCluskey J, and Gherardin NA 2019. The biology and functional importance of MAIT cells. Nat Immunol 20: 1110–1128. [DOI] [PubMed] [Google Scholar]
  • 89.Toubal A, Nel I, Lotersztajn S, and Lehuen A. 2019. Mucosal-associated invariant T cells and disease. Nat Rev Immunol 19: 643–657. [DOI] [PubMed] [Google Scholar]
  • 90.Provine NM, and Klenerman P. 2020. MAIT Cells in Health and Disease. Annu Rev Immunol 38: 203–228. [DOI] [PubMed] [Google Scholar]
  • 91.Kjer-Nielsen L, Patel O, Corbett AJ, Le Nours J, Meehan B, Liu L, Bhati M, Chen Z, Kostenko L, Reantragoon R, Williamson NA, Purcell AW, Dudek NL, McConville MJ, O’Hair RA, Khairallah GN, Godfrey DI, Fairlie DP, Rossjohn J, and McCluskey J. 2012. MR1 presents microbial vitamin B metabolites to MAIT cells. Nature 491: 717–723. [DOI] [PubMed] [Google Scholar]
  • 92.Keller AN, Eckle SB, Xu W, Liu L, Hughes VA, Mak JY, Meehan BS, Pediongco T, Birkinshaw RW, Chen Z, Wang H, D’Souza C, Kjer-Nielsen L, Gherardin NA, Godfrey DI, Kostenko L, Corbett AJ, Purcell AW, Fairlie DP, McCluskey J, and Rossjohn J. 2017. Drugs and drug-like molecules can modulate the function of mucosal-associated invariant T cells. Nat Immunol 18: 402–411. [DOI] [PubMed] [Google Scholar]
  • 93.Koay HF, Gherardin NA, Enders A, Loh L, Mackay LK, Almeida CF, Russ BE, Nold-Petry CA, Nold MF, Bedoui S, Chen Z, Corbett AJ, Eckle SB, Meehan B, d’Udekem Y, Konstantinov IE, Lappas M, Liu L, Goodnow CC, Fairlie DP, Rossjohn J, Chong MM, Kedzierska K, Berzins SP, Belz GT, McCluskey J, Uldrich AP, Godfrey DI, and Pellicci DG 2016. A three-stage intrathymic development pathway for the mucosal-associated invariant T cell lineage. Nat Immunol 17: 1300–1311. [DOI] [PubMed] [Google Scholar]
  • 94.Jensen O, Trivedi S, Meier JD, Fairfax KC, Hale JS, and Leung DT 2022. A subset of follicular helper-like MAIT cells can provide B cell help and support antibody production in the mucosa. Sci Immunol 7: eabe8931. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 95.Vorkas CK, Krishna C, Li K, Aubé J, Fitzgerald DW, Mazutis L, Leslie CS, and Glickman MS 2022. Single-Cell Transcriptional Profiling Reveals Signatures of Helper, Effector, and Regulatory MAIT Cells during Homeostasis and Activation. J Immunol doi: 10.4049/jimmunol.2100522. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 96.Legoux F, Bellet D, Daviaud C, El Morr Y, Darbois A, Niort K, Procopio E, Salou M, Gilet J, Ryffel B, Balvay A, Foussier A, Sarkis M, El Marjou A, Schmidt F, Rabot S, and Lantz O. 2019. Microbial metabolites control the thymic development of mucosal-associated invariant T cells. Science 366: 494–499. [DOI] [PubMed] [Google Scholar]
  • 97.Toubal A, Kiaf B, Beaudoin L, Cagninacci L, Rhimi M, Fruchet B, da Silva J, Corbett AJ, Simoni Y, Lantz O, Rossjohn J, McCluskey J, Lesnik P, Maguin E, and Lehuen A. 2020. Mucosal-associated invariant T cells promote inflammation and intestinal dysbiosis leading to metabolic dysfunction during obesity. Nat Commun 11: Article 3755. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 98.Constantinides MG, Link VM, Tamoutounour S, Wong AC, Perez-Chaparro PJ, Han SJ, Chen YE, Li K, Farhat S, Weckel A, Krishnamurthy SR, Vujkovic-Cvijin I, Linehan JL, Bouladoux N, Merrill ED, Roy S, Cua DJ, Adams EJ, Bhandoola A, Scharschmidt TC, Aubé J, Fischbach MA, and Belkaid Y. 2019. MAIT cells are imprinted by the microbiota in early life and promote tissue repair. Science 366: eaax6624. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 99.Leng T, Akther HD, Hackstein CP, Powell K, King T, Friedrich M, Christoforidou Z, McCuaig S, Neyazi M, Arancibia-Cárcamo CV, Hagel J, Powrie F, Peres RS, Millar V, Ebner D, Lamichhane R, Ussher J, Hinks TSC, Marchi E, Willberg C, Klenerman P, and Investigators OI 2019. TCR and Inflammatory Signals Tune Human MAIT Cells to Exert Specific Tissue Repair and Effector Functions. Cell Rep 28: 3077–3091.e3075. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 100.Jensen PE, Sullivan BA, Reed-Loisel LM, and Weber DA 2004. Qa-1, a nonclassical class I histocompatibility molecule with roles in innate and adaptive immunity. Immunol Res 29: 81–92. [DOI] [PubMed] [Google Scholar]
  • 101.Sheng H, Dasgupta S, and Kumar V. 2021. Involvement of Qa-1/HLA-E-restricted CD8+ T cells in anti-microbial and anti-cancer immunity as well as in immune regulation. Crit Rev Immunol 41: 39–53. [DOI] [PubMed] [Google Scholar]
  • 102.Nagarajan NA, Gonzalez F, and Shastri N. 2012. Nonclassical MHC class Ib-restricted cytotoxic T cells monitor antigen processing in the endoplasmic reticulum. Nat Immunol 13: 579–586. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 103.Guan J, Yang SJ, Gonzalez F, Yin Y, and Shastri N. 2017. Antigen Processing in the Endoplasmic Reticulum Is Monitored by Semi-Invariant αβ TCRs Specific for a Conserved Peptide-Qa-1. J Immunol 198: 2017–2027. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 104.Van Kaer L. 2010. Comeback kids: CD8+ suppressor T cells are back in the game. J Clin Invest 120: 3432–3434. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 105.Anderson CK, and Brossay L. 2016. The role of MHC class Ib-restricted T cells during infection. Immunogenetics 68: 677–691. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 106.Sheng H, Marrero I, Maricic I, Fanchiang SS, Zhang S, Sant’Angelo DB, and Kumar V. 2019. Distinct PLZF+CD8αα+ Unconventional T Cells Enriched in Liver Use a Cytotoxic Mechanism to Limit Autoimmunity. J Immunol 203: 2150–2162. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 107.Sottile R, Panjwani MK, Lau CM, Daniyan AF, Tanaka K, Barker JN, Brentjens RJ, Sun JC, Le Luduec JB, and Hsu KC 2021. Human cytomegalovirus expands a CD8. Sci Immunol 6: eabe6968. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 108.Loveland B, Wang CR, Yonekawa H, Hermel E, and Lindahl KF 1990. Maternally transmitted histocompatibility antigen of mice: a hydrophobic peptide of a mitochondrially encoded protein. Cell 60: 971–980. [DOI] [PubMed] [Google Scholar]
  • 109.Ploss A, Leiner I, and Pamer EG 2005. Distinct regulation of H2-M3-restricted memory T cell responses in lymph node and spleen. J Immunol 175: 5998–6005. [DOI] [PubMed] [Google Scholar]
  • 110.Cho H, Bediako Y, Xu H, Choi HJ, and Wang CR 2011. Positive selecting cell type determines the phenotype of MHC class Ib-restricted CD8+ T cells. Proc Natl Acad Sci U S A 108: 13241–13246. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 111.Kerksiek KM, Busch DH, Pilip IM, Allen SE, and Pamer EG 1999. H2-M3-restricted T cells in bacterial infection: rapid primary but diminished memory responses. J Exp Med 190: 195–204. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 112.Seaman MS, Wang CR, and Forman J. 2000. MHC class Ib-restricted CTL provide protection against primary and secondary Listeria monocytogenes infection. J Immunol 165: 5192–5201. [DOI] [PubMed] [Google Scholar]
  • 113.Xu H, Chun T, Choi HJ, Wang B, and Wang CR 2006. Impaired response to Listeria in H2-M3-deficient mice reveals a nonredundant role of MHC class Ib-specific T cells in host defense. J Exp Med 203: 449–459. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 114.Linehan JL, Harrison OJ, Han SJ, Byrd AL, Vujkovic-Cvijin I, Villarino AV, Sen SK, Shaik J, Smelkinson M, Tamoutounour S, Collins N, Bouladoux N, Dzutsev A, Rosshart SP, Arbuckle JH, Wang CR, Kristie TM, Rehermann B, Trinchieri G, Brenchley JM, O’Shea JJ, and Belkaid Y. 2018. Non-classical Immunity Controls Microbiota Impact on Skin Immunity and Tissue Repair. Cell 172: 784–796.e718. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 115.Ribot JC, Lopes N, and Silva-Santos B. 2021. γδ T cells in tissue physiology and surveillance. Nat Rev Immunol 21: 221–232. [DOI] [PubMed] [Google Scholar]
  • 116.Chien YH, Meyer C, and Bonneville M. 2014. γδ T cells: first line of defense and beyond. Annu Rev Immunol 32: 121–155. [DOI] [PubMed] [Google Scholar]
  • 117.Deseke M, and Prinz I. 2020. Ligand recognition by the γδ TCR and discrimination between homeostasis and stress conditions. Cell Mol Immunol 17: 914–924. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 118.Kreslavsky T, Savage AK, Hobbs R, Gounari F, Bronson R, Pereira P, Pandolfi PP, Bendelac A, and von Boehmer H. 2009. TCR-inducible PLZF transcription factor required for innate phenotype of a subset of gammadelta T cells with restricted TCR diversity. Proc Natl Acad Sci U S A 106: 12453–12458. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 119.Hayday AC 2019. γδ T Cell Update: Adaptate Orchestrators of Immune Surveillance. J Immunol 203: 311–320. [DOI] [PubMed] [Google Scholar]
  • 120.Junqueira C, Polidoro RB, Castro G, Absalon S, Liang Z, Sen Santara S, Crespo Â, Pereira DB, Gazzinelli RT, Dvorin JD, and Lieberman J. 2021. γδ T cells suppress Plasmodium falciparum blood-stage infection by direct killing and phagocytosis. Nat Immunol 22: 347–357. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 121.Kohlgruber AC, Gal-Oz ST, LaMarche NM, Shimazaki M, Duquette D, Koay HF, Nguyen HN, Mina AI, Paras T, Tavakkoli A, von Andrian U, Uldrich AP, Godfrey DI, Banks AS, Shay T, Brenner MB, and Lynch L. 2018. γδ T cells producing interleukin-17A regulate adipose regulatory T cell homeostasis and thermogenesis. Nat Immunol 19: 464–474. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 122.Hu B, Jin C, Zeng X, Resch JM, Jedrychowski MP, Yang Z, Desai BN, Banks AS, Lowell BB, Mathis D, and Spiegelman BM 2020. γδ T cells and adipocyte IL-17RC control fat innervation and thermogenesis. Nature 578: 610–614. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 123.MacLeod AS, Hemmers S, Garijo O, Chabod M, Mowen K, Witherden DA, and Havran WL 2013. Dendritic epidermal T cells regulate skin antimicrobial barrier function. J Clin Invest 123: 4364–4374. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 124.Girardi M, Oppenheim DE, Steele CR, Lewis JM, Glusac E, Filler R, Hobby P, Sutton B, Tigelaar RE, and Hayday AC 2001. Regulation of cutaneous malignancy by gammadelta T cells. Science 294: 605–609. [DOI] [PubMed] [Google Scholar]
  • 125.Nazmi A, McClanahan KG, and Olivares-Villagomez D. 2021. Unconventional intestinal epithelial lymphocytes in health and disease. Crit Rev Immunol 41: 23–38. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 126.Ruscher R, Lee ST, Salgado OC, Breed ER, Osum SH, and Hogquist KA 2020. Intestinal CD8αα IELs derived from two distinct thymic precursors have staggered ontogeny. J Exp Med 217: e20192336. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 127.Ma H, Qiu Y, and Yang H. 2021. Intestinal intraepithelial lymphocytes: Maintainers of intestinal immune tolerance and regulators of intestinal immunity. J Leukoc Biol 109: 339–347. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 128.He S, Kahles F, Rattik S, Nairz M, McAlpine CS, Anzai A, Selgrade D, Fenn AM, Chan CT, Mindur JE, Valet C, Poller WC, Halle L, Rotllan N, Iwamoto Y, Wojtkiewicz GR, Weissleder R, Libby P, Fernández-Hernando C, Drucker DJ, Nahrendorf M, and Swirski FK 2019. Gut intraepithelial T cells calibrate metabolism and accelerate cardiovascular disease. Nature 566: 115–119. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 129.Jameson SC, Lee YJ, and Hogquist KA 2015. Innate memory T cells. Adv Immunol 126: 173–213. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 130.Kwesi-Maliepaard EM, Jacobs H, and van Leeuwen F. 2021. Signals for antigen-independent differentiation of memory CD8. Cell Mol Life Sci 78: 6395–6408. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 131.Moudra A, Niederlova V, Novotny J, Schmiedova L, Kubovciak J, Matejkova T, Drobek A, Pribikova M, Stopkova R, Cizkova D, Neuwirth A, Michalik J, Krizova K, Hudcovic T, Kolar M, Kozakova H, Kreisinger J, Stopka P, and Stepanek O. 2021. Phenotypic and Clonal Stability of Antigen-Inexperienced Memory-like T Cells across the Genetic Background, Hygienic Status, and Aging. J Immunol 206: 2109–2121. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 132.Weinreich MA, Odumade OA, Jameson SC, and Hogquist KA 2010. T cells expressing the transcription factor PLZF regulate the development of memory-like CD8+ T cells. Nat Immunol 11: 709–716. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 133.Miller CH, Klawon DEJ, Zeng S, Lee V, Socci ND, and Savage PA 2020. Eomes identifies thymic precursors of self-specific memory-phenotype CD8. Nat Immunol 21: 567–577. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 134.Drobek A, Moudra A, Mueller D, Huranova M, Horkova V, Pribikova M, Ivanek R, Oberle S, Zehn D, McCoy KD, Draber P, and Stepanek O. 2018. Strong homeostatic TCR signals induce formation of self-tolerant virtual memory CD8 T cells. EMBO J 37: e98518. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 135.Hussain T, and Quinn KM 2019. Similar but different: virtual memory CD8 T cells as a memory-like cell population. Immunol Cell Biol 97: 675–684. [DOI] [PubMed] [Google Scholar]
  • 136.Pribikova M, Moudra A, and Stepanek O. 2018. Opinion: Virtual memory CD8 T cells and lymphopenia-induced memory CD8 T cells represent a single subset: Homeostatic memory T cells. Immunol Lett 203: 57–61. [DOI] [PubMed] [Google Scholar]
  • 137.Mukund K, Nayak P, Ashokkumar C, Rao S, Almeda J, Betancourt-Garcia MM, Sindhi R, and Subramaniam S. 2021. Immune Response in Severe and Non-Severe Coronavirus Disease 2019 (COVID-19) Infection: A Mechanistic Landscape. Front Immunol 12: Article 738073. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 138.Björkström NK, and Ponzetta A. 2021. Natural killer cells and unconventional T cells in COVID-19. Curr Opin Virol 49: 176–182. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 139.Witkowski M, Tizian C, Ferreira-Gomes M, Niemeyer D, Jones TC, Heinrich F, Frischbutter S, Angermair S, Hohnstein T, Mattiola I, Nawrath P, McEwen S, Zocche S, Viviano E, Heinz GA, Maurer M, Kölsch U, Chua RL, Aschman T, Meisel C, Radke J, Sawitzki B, Roehmel J, Allers K, Moos V, Schneider T, Hanitsch L, Mall MA, Conrad C, Radbruch H, Duerr CU, Trapani JA, Marcenaro E, Kallinich T, Corman VM, Kurth F, Sander LE, Drosten C, Treskatsch S, Durek P, Kruglov A, Radbruch A, Mashreghi MF, and Diefenbach A. 2021. Untimely TGFβ responses in COVID-19 limit antiviral functions of NK cells. Nature 600: 295–301. [DOI] [PubMed] [Google Scholar]
  • 140.Koay H-F, Gherardin NA, Nguyen THO, Zhang W, Habel JR, Seneviratna R, James F, Holmes NE, Smibert OC, Gordon CL, Trubiano JA, Kedzierska K, and Godfrey DI 2022. Are NKT cells a useful predictor of COVID-19 severity? Immunity 55:185–187. [DOI] [PMC free article] [PubMed] [Google Scholar]

RESOURCES